Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Fluoxetine in Children and Adolescents With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~Meets diagnostic criteria for autism~--Prior/Concurrent Therapy--~Other:~* At least 3 months since prior electroconvulsive therapy~* At least 1 month since prior investigational drugs or treatment with any drug known to cause major organ toxicity~* At least 2 weeks since prior monoamine oxidase inhibitors~* At least 6 weeks since prior long acting phenothiazines~* At least 1 week since prior other psychotropic drugs~* No prior fluoxetine of 20 mg/day for 6 weeks~* At least 6 weeks since prior fluoxetine~* No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)~* No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise permitted)~* Prior participation in another serotonin reuptake inhibitor trial allowed~--Patient Characteristics--~Hematopoietic: No significant hematopoietic disease~Hepatic: No prior or concurrent liver disease~Renal: No prior or concurrent kidney disease~Cardiovascular:~* No significant cardiovascular disease~* No abnormal EKG~Neurological:~* No prior seizure disorder or high risk development of seizures~* No prior cerebrovascular disease~* No prior brain trauma~Other:~* Not pregnant or nursing~* Negative pregnancy test~* No unstable major medical illness or systemic disease~* No moderate or severe mental retardation and motor deficits (IQ less than 50)~* No family history of bipolar disorder~* No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective, organic, or bipolar disorders)~* No significant autoaggressive behavior or serious suicidal risk~* No prior or concurrent gastrointestinal conditions~* No unstable endocrine disease (e.g., hypo or hyperthyroidism)~* No prior or concurrent malignancy~* Must be able to tolerate tapering of psychoactive medication~* No history of hypersensitivity or severe side effects to fluoxetine or other serotonin reuptake inhibitors~* No history of severe personality disorder or noncompliance

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).